Understanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)

Simple item page
dc.contributor.authorJoshi, Jay
dc.contributor.supervisorLum, Julian J.
dc.date.accessioned2020-12-22T04:42:08Z
dc.date.available2020-12-22T04:42:08Z
dc.date.copyright2020en_US
dc.date.issued2020-12-21
dc.degree.departmentDepartment of Biochemistry and Microbiologyen_US
dc.degree.levelMaster of Science M.Sc.en_US
dc.description.abstractProstate cancer is the most common cancer in men and the third leading cause of cancer-related deaths in Canadian men. Despite hormone and radiation therapies, most patients progress to late-stage metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA617 radioligand therapy (rLT) is a radioactive biochemical substance that targets the human prostate-specific membrane antigen (hPSMA). This rLT has been used in compassionate trials in mCRPC patients and has been demonstrated significant clinical efficacy. However, recent findings suggest that this efficacy is short-lived, and most patients exhibit tumor recurrence [96]. Here we establish a murine model to study the anti-tumor effects and the corresponding immune response of 177Lu-PSMA617 rLT on prostate cancer. We generated a doxycycline-inducible hPSMA-expressing murine prostate cancer (hPSMA TRAMP-C2) cell line with high binding responses to PSMA617. Using this system, we evaluated the in vitro and in vivo binding of 177Lu-PSMA617 to the hPSMA TRAMP-C2 cell line. Here, we show that the hPSMA TRAMP-C2 cell line expresses hPSMA upon doxycycline induction and that 177Lu-PSMA617 can bind to its target in vitro and in vivo. Together, these results show that the developed hPSMA TRAMP-C2 cell line can be used to investigate therapeutic and immunological responses targeted against PSMA in prostate cancer.en_US
dc.description.scholarlevelGraduateen_US
dc.identifier.urihttp://hdl.handle.net/1828/12479
dc.languageEnglisheng
dc.language.isoenen_US
dc.rightsAvailable to the World Wide Weben_US
dc.subjectProstate canceren_US
dc.subjectProstateen_US
dc.subjectPCaen_US
dc.subjectImmunologyen_US
dc.subjectImmunotherapyen_US
dc.subjectCanceren_US
dc.subjectJay Joshien_US
dc.subjectRadioligand therapyen_US
dc.subjectJulian Lumen_US
dc.titleUnderstanding the mechanism of 177Lu- PSMA617 radioligand therapy and evaluating its potential role in the treatment of metastatic castrate resistant prostate cancer (mCRPC)en_US
dc.typeThesisen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Joshi_Jay_MSc_2020.pdf
Size:
2.33 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Electronic Theses and Dissertations (ETD)
Theses (Biochemistry and Microbiology)
 
University of Victoria Libraries

We acknowledge and respect the Lək̓ʷəŋən (Songhees and Esquimalt) Peoples on whose territory the university stands, and the Lək̓ʷəŋən and W̱SÁNEĆ Peoples whose historical relationships with the land continue to this day.